The company has not filed an annual or quarterly report since its Q3 FY2018 10-Q, filed Nov 13, 2018. Its latest SEC filing is a RW from Sep 19, 2019.
10-Q for Q3 FY2018, filed Nov 13, 2018
The sections below describe the company as of the FY2017 annual report.
Develops human antibody-based treatments and imaging products for cancer, including pancreatic and other cancers.
10-K for FY2017, filed Apr 2, 2018We are a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the…View ↗
Our clinical development programs are centered around our HuMab-5B1 human antibody, which we have tested in 56 patients as a monotherapy…View ↗
The Phase 1a clinical trial of MVT-2163 was intended to evaluate our next generation diagnostic PET imaging agent in patients with locally…View ↗
Receives grant funding for covered internal and subcontractor costs as those costs are incurred, once the grant is approved for payment.
10-K for FY2017, filed Apr 2, 2018Revenue from grants is based upon internal and subcontractor costs incurred that are specifically covered by the grant, including a…View ↗
$1.3M
10-K for FY2015, filed Mar 14, 2016
$1.3M ↗
Plans to license product candidates to larger biopharmaceutical companies or work with them through strategic alliances, rather than sell through its own sales force.
10-K for FY2017, filed Apr 2, 2018Marketing and SalesView ↗
No. It lost $18.1M in FY2015.
10-K for FY2015, filed Mar 14, 2016
10-K for FY2015, filed Mar 14, 2016
−$18.1MView ↗
10-K for FY2015, filed Mar 14, 2016
−$18.1MView ↗
10-K for FY2015, filed Mar 14, 2016
−$10.6MView ↗
10-Q for Q3 FY2018, filed Nov 13, 2018
$340.7KView ↗
8-K, filed Mar 25, 2019
On March 21, 2019, MabVax Therapeutics Holdings, Inc. (the “Company”) filed a voluntary petition for reorganization relief under Chapter 11…View ↗
8-K, filed Jan 4, 2019
On January 4, 2019, MabVax Therapeutics Holdings, Inc. (the “Company”) issued a press release announcing the Company had entered into…View ↗
8-K, filed Jul 9, 2018
Pursuant to the terms of the Agreement, Boehringer Ingelheim acquired all rights to the Company’s program targeting a glycan commonly…View ↗
8-K, filed Jul 5, 2018
As previously disclosed in a Current Report on Form 8-K filed on July 2, 2018 (the “July 2, 2018 Current Report”), MabVax Therapeutics…View ↗
Grew.
Revenue grew 4.0x in 1 year, from $314.2K in FY2014 to $1.3M in FY2015, about 303% a year.
10-K for FY2015, filed Mar 14, 2016
Competes with AbCellera Biologics, Agenus, Atreca, Immunomedics, Theraclone Sciences, and Trellis Bioscience
10-K for FY2017, filed Apr 2, 2018There are several companies engaged in human antibody development and imaging that could compete in similar clinical areas, including…View ↗
Loading...
